Themis Medicare Reports Positive Financial Results for Q1 FY25, Reflecting Growth Potential
Themis Medicare, a smallcap pharmaceutical company, has recently announced its financial results for the quarter ending June 2024. The company’s stock has been given a ‘Hold’ call by MarketsMOJO.
According to the financials, Themis Medicare has shown a positive performance in the quarter, with a score of 14 compared to -6 in the previous 3 months. This indicates a significant improvement in the company’s financials.
One of the key factors contributing to this positive performance is the growth in Profit Before Tax less Other Income (PBT) – Quarterly, which has increased by 149.6% to Rs 30.39 crore compared to the average PBT of the previous four quarters at Rs 12.18 crore. This shows a very positive trend in the near term.
Similarly, the Profit After Tax (PAT) – Quarterly has also shown a growth of 126.8% to Rs 24.68 crore compared to the average PAT of the previous four quarters at Rs 10.88 crore. This indicates a very positive trend in the near term.
The company’s ability to manage interest payments has also improved, with the Operating Profit to Interest – Quarterly being the highest at 12.36 times in the last five quarters.
In terms of sales, Themis Medicare has shown a positive trend with the Net Sales – Quarterly being the highest at Rs 122.99 crore in the last five quarters. This also reflects a growth of 28.9% compared to the average Net Sales of the previous four quarters at Rs 95.44 crore.
The Operating Profit (PBDIT) – Quarterly has also shown a positive trend, being the highest at Rs 29.18 crore in the last five quarters. This indicates a positive trend in the near term.
Furthermore, the company’s efficiency has improved with the Operating Profit Margin – Quarterly being the highest at 23.73% in the last five quarters.
Overall, Themis Medicare has shown a positive financial performance in the quarter ending June 2024, with the highest PBT and PAT in the last five quarters. This reflects a positive trend in the near term and highlights the company’s growth potential in the pharmaceutical industry.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
{{text.big_txt}}
{{text .small_txt}}
{{dashverdictresult.dashboard.stock_details.short_name}}
SEND BY EMAIL
Register now to see if the stock’s characteristics match your investment style
Subscribe now to see if the stock's characteristics match your investment style
{{dashverdictresult.dashboard.risk_return_voltality.risk_type}}, {{dashverdictresult.dashboard.risk_return_voltality.return_type}}
| {{ value[0] }} | {{ value[1] }} | {{ value[2] }} | {{ value[3] }} |
| {{ value[0] }} | {{ value[1] }} | {{ value[2] }} | {{ value[3] }} |
Create your portfolio and know how much should this stock be in your portfolio
Subscribe now to know how much you should hold in this stock
We have found 2 better stocks that you can consider
{{dashverdictresult.dashboard.return_text}}
Investors Returns (3 years) –
| Period | 6M | 1Y | 2Y | 3Y |
| {{ keyd.val }} | ||||
| {{ keyd.val }} |
Quality: {{dashverdictresult.dashboard.dotsummary.q_txt}}
Valuation: {{dashverdictresult.dashboard.dotsummary.v_txt}}
Quarterly Financial Trend: {{dashverdictresult.dashboard.dotsummary.f_txt}}
Technicals: {{dashverdictresult.dashboard.dotsummary.tech_txt}}
Stock Info:
BSE – {{dashverdictresult.dashboard.stock_details.scripcode}}/ NSE – {{dashverdictresult.dashboard.stock_details.symbol}}
Market Cap – {{dashverdictresult.dashboard.priceinfo.mcap_class}} (Rs. {{dashverdictresult.dashboard.priceinfo.mcap| number :0}} cr)
Sector – {{dashverdictresult.dashboard.stock_details.ind_name}}
52 w H/L (Rs.) – {{dashverdictresult.dashboard.priceinfo.wk_high52}}/{{dashverdictresult.dashboard.priceinfo.wk_low52}}
Average vol (6M) – {{dashverdictresult.dashboard.priceinfo.vol}}
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
